Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

Upregulation of inhibitory receptors, such as lymphocyte activation gene-3 (LAG-3), may limit the antitumor activity of therapeutic antibodies targeting the programmed cell death protein-1 (PD-1) pathway. We describe the binding properties of ezabenlimab, an anti-human PD-1 antibody, and BI 754111,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zettl, Markus, Wurm, Melanie, Schaaf, Otmar, Mostböck, Sven, Tirapu, Iñigo, Apfler, Ilse, Lorenz, Ivo C., Frego, Lee, Kenny, Cynthia, Thibodeau, Michael, Oquendo Cifuentes, Elisa, Reschke, Markus, Moll, Jürgen, Kraut, Norbert, Vogt, Anne, Sedgwick, Jonathon D., Waizenegger, Irene C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225207/
https://www.ncbi.nlm.nih.gov/pubmed/35756842
http://dx.doi.org/10.1080/2162402X.2022.2080328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225207/
https://www.ncbi.nlm.nih.gov/pubmed/35756842
http://dx.doi.org/10.1080/2162402X.2022.2080328

Ejemplares similares